{
 "as_of": "2026-11-06",
 "cmr": "se-cm-kg/XSTO/SE0009973563",
 "fence": "The page is the record's research on the issuer — no analyst, no rating, no view.",
 "markdown": "The page is the record's research on the issuer — no analyst, no rating, no view.\n\n# Xspray Pharma AB (Nasdaq Stockholm: SE0009973563) — research page\n\nAs of 2026-11-06 · se-cm-kg · record version 1\n\n## Identity and listing\n\nThe issuer is Xspray Pharma AB, listed on Nasdaq Stockholm under ticker SE0009973563, with ISIN SE0009973563 and LEI 549300NGRQCNZ3X4L157. Security type, segment, sector and jurisdiction are not on the record. Listing status is listed, not halted.\n\n## The disclosure read\n\nThe record holds 28 filings across 22 filing days in the window 2025-11-06 to 2026-11-06. The median gap between filing days is 9 days, against a Nasdaq Stockholm median of 9.5 days. The latest filing is dated 2026-11-06 and is an Interim report (Q1 and Q3), with a latency of 0 days to the record date of 2026-11-06. The Nasdaq Stockholm median latency is 7.0 days and the median filings per issuer is 30.0. The sector peer median is not on the record.\n\n## Auditor\n\nThe auditor and its location are not on the record. Auditor changes are not on the record, as this register has no lifecycle type map yet.\n\n## Events and halts\n\nListing, delisting, name change, domicile change and segment move are not on the record, as this register has no lifecycle type map yet. The halt flag shows the issuer as listed, not halted.\n\n## Orderability\n\nThe outcome is not determinable. The chapter's orderability section carries no client categories, so the outcome cannot name its client category. The rule version is acm-68000/se/mifid-ii-product-governance/r1, and the chapter is as of 2026-11-04.\n\n## Coverage\n\nOne research house is named on the issuer's investor-relations page: Redeye.\n\n## Open research\n\nNo openly published research notes were found on the record.\n\n## Licensed\n\nLicensed research: none loaded. A licensed row is served only to an agent whose firm holds that licence (licensor, entitlement). No licensed row is loaded.\n\n## As-of depth\n\nThe market's vintage is not sealed. No issuer years are sealed, the market's earliest sealed date is not on the record, and the live record start date is not on the record.\n\n## Sources\n\n7 source pages are named on this page; every value above carries its own source page and read date in the numbers.\n\n- https://firds.esma.europa.eu/firds/ (identity.exchange)\n- https://mapping.gleif.org/api/v2/isin-lei/latest/download (identity.lei)\n- https://mcp.se-cm-kg.ai/events/XSTO/SE0009973563 (the disclosure lines)\n- https://api.news.eu.nasdaq.com/news/query.action?globalGroup=exchangeNotice&globalName=ExchangenewsFilter|FirstNorthInformation (the halt flag)\n- https://se.eu-cm-kg.ai/book/aio.json (the orderability chapter)\n- https://xspraypharma.com/investors/share-information/ (coverage)\n- https://mcp.se-cm-kg.ai/record/XSTO/SE0009973563 (the record)\n",
 "market": "SE",
 "node": "se-cm-kg",
 "numbers": {
  "as_of_depth": {
   "issuer_years_sealed": [],
   "live_record_began": null,
   "node_history_from": null,
   "node_years_sealed": [],
   "note": "the SE vintage is not sealed; the record is the live record as of 2026-11-06",
   "record_version": 1,
   "sealed": false
  },
  "auditor": {
   "auditor": {
    "market": "SE",
    "state": "not_on_record"
   },
   "auditor_firm_id": {
    "market": "SE",
    "state": "not_on_record"
   },
   "auditor_location": {
    "market": "SE",
    "state": "not_on_record"
   },
   "changes": {
    "market": "SE",
    "reason": "no lifecycle type map for this register yet (SHELF-01: us and ca first)",
    "state": "not_on_record"
   }
  },
  "cmr": "se-cm-kg/XSTO/SE0009973563",
  "coverage": {
   "count": 1,
   "houses": [
    {
     "analyst": "Filip Einarsson",
     "house": "Redeye",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-12",
     "source": "https://xspraypharma.com/investors/share-information/",
     "state": "sourced"
    }
   ],
   "pages_checked": [
    {
     "page": "https://xspraypharma.com/investors/share-information/",
     "result": "read: 1 of 2 named houses found on the page"
    }
   ],
   "read_by": "Perplexity sonar (search) · page read by this rail",
   "read_date": "2026-11-12",
   "since": "not stated on the page read",
   "state": "found"
  },
  "disclosure": {
   "against": {
    "exchange": {
     "issuers": 398,
     "median_cadence_gap_days": 9.5,
     "median_filings": 30,
     "median_latency_days": 7,
     "name": "Nasdaq Stockholm"
    },
    "sector": {
     "market": "SE",
     "state": "not_on_record"
    }
   },
   "by_type": {
    "Annual Financial Report": 1,
    "Changes board/management/auditors": 1,
    "Decisions of general meeting": 1,
    "Financial Statement Release": 1,
    "Half Year financial report": 1,
    "Inside information": 5,
    "Interim report (Q1 and Q3)": 2,
    "Investor News": 12,
    "Notice to general meeting": 1,
    "Other information disclosed according to the rules of the Exchange": 2,
    "Total number of voting rights and capital": 1
   },
   "cadence_median_gap_days": 9,
   "filing_days": 22,
   "filings": 28,
   "latency_days": 0,
   "latest": [
    {
     "category": "Interim report (Q1 and Q3)",
     "date": "2026-11-06",
     "source": "https://view.news.eu.nasdaq.com/view?id=bc25de1d427d61de71f39c1f0969dc006&lang=en&src=listed",
     "title": "Xspray Pharma publishes Interim Report for the third quarter 2026",
     "type": "Interim report (Q1 and Q3)"
    },
    {
     "category": "Inside information",
     "date": "2026-11-06",
     "source": "https://view.news.eu.nasdaq.com/view?id=b0f3f981122ca47735424230ecd6a9a4b&lang=en&src=listed",
     "title": "Xspray resolves on a rights issue of approximately SEK 90 million with an over-allotment issue of approximately SEK 72 million",
     "type": "Inside information"
    },
    {
     "category": "Inside information",
     "date": "2026-11-05",
     "source": "https://view.news.eu.nasdaq.com/view?id=b414e81a873c7951dbf4378ca909b870a&lang=en&src=listed",
     "title": "Xspray Pharma notified that the FDA has commenced an inspection at NerPharMa's manufacturing facility",
     "type": "Inside information"
    },
    {
     "category": "Investor News",
     "date": "2026-10-02",
     "source": "https://view.news.eu.nasdaq.com/view?id=b970f723b04340d3c5c739a08ca870030&lang=en&src=listed",
     "title": "Xspray Pharma provides regulatory status update for Dasynoc and Nilopki",
     "type": "Investor News"
    },
    {
     "category": "Investor News",
     "date": "2026-09-23",
     "source": "https://view.news.eu.nasdaq.com/view?id=b1ff124165fe0f9509a8f364fa5481f76&lang=en&src=listed",
     "title": "Xspray Pharma to present CML data supporting differentiation of Dasynoc and Nilopki",
     "type": "Investor News"
    }
   ],
   "latest_filing_date": "2026-11-06",
   "read": "the node's event lines (list_events_since), as get_filings serves them",
   "source": "https://mcp.se-cm-kg.ai/events/XSTO/SE0009973563",
   "window": {
    "from": "2025-11-06",
    "to": "2026-11-06"
   }
  },
  "identity": {
   "exchange": {
    "read_by": "allooloo-cm-kg/eu-sources/se roster.py",
    "read_date": "2026-11-06",
    "read_date_basis": "the record version as_of",
    "source": "https://firds.esma.europa.eu/firds/ (ESMA FIRDS FULINS_E 2026-11-07: FULINS_E_20261107_01of02.zip, FULINS_E_20261107_02of02.zip)",
    "state": "sourced",
    "value": "Nasdaq Stockholm"
   },
   "isin": {
    "read_by": "allooloo-cm-kg/eu-sources/se roster.py",
    "read_date": "2026-11-06",
    "read_date_basis": "the record version as_of",
    "source": "https://firds.esma.europa.eu/firds/ (ESMA FIRDS FULINS_E 2026-11-07: FULINS_E_20261107_01of02.zip, FULINS_E_20261107_02of02.zip)",
    "state": "sourced",
    "value": "SE0009973563"
   },
   "jurisdiction": {
    "market": "SE",
    "state": "not_on_record"
   },
   "lei": {
    "read_by": "GLEIF ISIN-to-LEI mapping file (daily), LEI by exact ISIN",
    "read_date": "2026-11-09",
    "read_date_basis": "the field",
    "source": "https://mapping.gleif.org/api/v2/isin-lei/latest/download (ISIN SE0009973563)",
    "state": "sourced",
    "value": "549300NGRQCNZ3X4L157"
   },
   "name": {
    "read_by": "allooloo-cm-kg/eu-sources/se roster.py",
    "read_date": "2026-11-06",
    "read_date_basis": "the record version as_of",
    "source": "https://firds.esma.europa.eu/firds/ (ESMA FIRDS FULINS_E 2026-11-07: FULINS_E_20261107_01of02.zip, FULINS_E_20261107_02of02.zip)",
    "state": "sourced",
    "value": "Xspray Pharma AB"
   },
   "sector": {
    "market": "SE",
    "state": "not_on_record"
   },
   "security_type": {
    "market": "SE",
    "state": "not_on_record"
   },
   "segment": {
    "market": "SE",
    "state": "not_on_record"
   },
   "ticker": {
    "read_by": "allooloo-cm-kg/eu-sources/se roster.py",
    "read_date": "2026-11-06",
    "read_date_basis": "the record version as_of",
    "source": "https://firds.esma.europa.eu/firds/ (ESMA FIRDS FULINS_E 2026-11-07: FULINS_E_20261107_01of02.zip, FULINS_E_20261107_02of02.zip)",
    "state": "sourced",
    "value": "SE0009973563"
   },
   "website": {
    "market": "SE",
    "state": "not_on_record"
   }
  },
  "licensed": {
   "columns": [
    "licensor",
    "entitlement",
    "title",
    "date",
    "source"
   ],
   "rows": [],
   "rule": "A licensed row is served only to an agent whose firm holds that licence (licensor, entitlement). No licensed row is loaded."
  },
  "lifecycle": {
   "delisting": {
    "market": "SE",
    "reason": "no lifecycle type map for this register yet (SHELF-01: us and ca first)",
    "state": "not_on_record"
   },
   "domicile_change": {
    "market": "SE",
    "reason": "no lifecycle type map for this register yet (SHELF-01: us and ca first)",
    "state": "not_on_record"
   },
   "listing": {
    "market": "SE",
    "reason": "no lifecycle type map for this register yet (SHELF-01: us and ca first)",
    "state": "not_on_record"
   },
   "name_change": {
    "market": "SE",
    "reason": "no lifecycle type map for this register yet (SHELF-01: us and ca first)",
    "state": "not_on_record"
   },
   "segment_move": {
    "market": "SE",
    "reason": "no lifecycle type map for this register yet (SHELF-01: us and ca first)",
    "state": "not_on_record"
   }
  },
  "market": "SE",
  "node": "se-cm-kg",
  "numbers_hash": "sha256:bb522bb2c0f051865fc97a3374998a420528acd20195cbf08cfd4e7d279292bb",
  "open_research": {
   "read_date": "2026-11-12",
   "rows": [],
   "state": "none_found"
  },
  "orderability": {
   "chapter_as_of": "2026-11-04",
   "client_categories": [],
   "determinable": false,
   "read": {
    "chapter": "https://se.eu-cm-kg.ai/book/aio.json",
    "door": "https://se.eu-cm-kg.ai/mcp",
    "tool": "get_orderability"
   },
   "reason": "the chapter's orderability section carries no client_categories: the outcome cannot name its client category",
   "rule_version": "acm-68000/se/mifid-ii-product-governance/r1",
   "section": "se.aio.v5"
  },
  "record": {
   "as_of": "2026-11-06",
   "url": "https://mcp.se-cm-kg.ai/record/XSTO/SE0009973563",
   "version": 1
  },
  "schema": "research-numbers v0.1 (USR-01, 2026-11-11)",
  "status": {
   "read_date": "2026-11-09",
   "source": "https://api.news.eu.nasdaq.com/news/query.action?globalGroup=exchangeNotice&globalName=ExchangenewsFilter|FirstNorthInformation",
   "value": "listed, not halted"
  }
 },
 "numbers_hash": "sha256:bb522bb2c0f051865fc97a3374998a420528acd20195cbf08cfd4e7d279292bb",
 "path": "/se/XSTO/SE0009973563",
 "schema": "research-page v0.1 (USR-02, 2026-11-11)",
 "sections": [
  {
   "id": "identity",
   "text": "The issuer is Xspray Pharma AB, listed on Nasdaq Stockholm under ticker SE0009973563, with ISIN SE0009973563 and LEI 549300NGRQCNZ3X4L157. Security type, segment, sector and jurisdiction are not on the record. Listing status is listed, not halted.",
   "title": "Identity and listing"
  },
  {
   "id": "disclosure",
   "text": "The record holds 28 filings across 22 filing days in the window 2025-11-06 to 2026-11-06. The median gap between filing days is 9 days, against a Nasdaq Stockholm median of 9.5 days. The latest filing is dated 2026-11-06 and is an Interim report (Q1 and Q3), with a latency of 0 days to the record date of 2026-11-06. The Nasdaq Stockholm median latency is 7.0 days and the median filings per issuer is 30.0. The sector peer median is not on the record.",
   "title": "The disclosure read"
  },
  {
   "id": "auditor",
   "text": "The auditor and its location are not on the record. Auditor changes are not on the record, as this register has no lifecycle type map yet.",
   "title": "Auditor"
  },
  {
   "id": "events",
   "text": "Listing, delisting, name change, domicile change and segment move are not on the record, as this register has no lifecycle type map yet. The halt flag shows the issuer as listed, not halted.",
   "title": "Events and halts"
  },
  {
   "id": "orderability",
   "text": "The outcome is not determinable. The chapter's orderability section carries no client categories, so the outcome cannot name its client category. The rule version is acm-68000/se/mifid-ii-product-governance/r1, and the chapter is as of 2026-11-04.",
   "title": "Orderability"
  },
  {
   "id": "coverage",
   "text": "One research house is named on the issuer's investor-relations page: Redeye.",
   "title": "Coverage"
  },
  {
   "id": "open_research",
   "text": "No openly published research notes were found on the record.",
   "title": "Open research"
  },
  {
   "id": "licensed",
   "text": "Licensed research: none loaded. A licensed row is served only to an agent whose firm holds that licence (licensor, entitlement). No licensed row is loaded.",
   "title": "Licensed"
  },
  {
   "id": "depth",
   "text": "The market's vintage is not sealed. No issuer years are sealed, the market's earliest sealed date is not on the record, and the live record start date is not on the record.",
   "title": "As-of depth"
  },
  {
   "id": "sources",
   "text": "7 source pages are named on this page; every value above carries its own source page and read date in the numbers.",
   "title": "Sources"
  }
 ],
 "sources": [
  {
   "for": "identity.exchange",
   "source": "https://firds.esma.europa.eu/firds/"
  },
  {
   "for": "identity.lei",
   "source": "https://mapping.gleif.org/api/v2/isin-lei/latest/download"
  },
  {
   "for": "the disclosure lines",
   "source": "https://mcp.se-cm-kg.ai/events/XSTO/SE0009973563"
  },
  {
   "for": "the halt flag",
   "source": "https://api.news.eu.nasdaq.com/news/query.action?globalGroup=exchangeNotice&globalName=ExchangenewsFilter|FirstNorthInformation"
  },
  {
   "for": "the orderability chapter",
   "source": "https://se.eu-cm-kg.ai/book/aio.json"
  },
  {
   "for": "coverage",
   "source": "https://xspraypharma.com/investors/share-information/"
  },
  {
   "for": "the record",
   "source": "https://mcp.se-cm-kg.ai/record/XSTO/SE0009973563"
  }
 ],
 "title": "Xspray Pharma AB (SE0009973563) — research page",
 "writer": {
  "by": "Claude through the platform account, Haiku class; one pass; checked against the numbers",
  "engine": "claude-haiku-5-5"
 }
}